Mural Oncology reports Q3 EPS ($1.87), consensus ($1.95)

“Mural launched as a stand-alone company one year ago with a mission to shepherd in the second wave of immuno-oncology for patients-IO 2.0-and we believe we are well on the path to realize that vision. With our deep expertise of protein engineering and cancer biology, we are working to address key limitations with cytokine therapies and unleash their full potential. We are now focused on clinical execution, with major readouts of our two potentially registrational studies of nemvaleukin in the first half of next year, and commercial readiness. We are also deepening our pipeline with candidate nominations for our IL-18 and IL-12 programs expected by the end of this year,” said Caroline Loew, Ph.D., CEO of Mural Oncology (MURA).